• 1
    Bargen JA. Chronic ulcerative colitis associated with malignant disease. Arch Surg 1928; 17: 56176.
  • 2
    Hughes RK. Reticulum cell sarcoma: a case possibly originating in regional enteritis. Ann Surg 1955; 21: 7703.
  • 3
    Forbes A & Reading NG. Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Alimentary Pharmacol Therapeutics 1995; 9: 46570.
  • 4
    Peppercom MA. 6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come. Am J Gastroenterol 1996; 91: 168990.
  • 5
    Bell S & Kamm MA. Antibodies to tumour necrosis factor α as treatment for Crohn’s disease. Lancet 2000; 355: 85860.DOI: 10.1016/s0140-6736(99)00442-0
  • 6
    Bunch C & Gatter KC. The lymphomas. In: Weatherall DJ, Ledingham JGG Warrell DA, eds. Oxford Textbook of Medicine. Oxford University press, Oxford, 1996: 3568–87.
  • 7
    Isaacson PG. B cell lymphomas of mucosa associated lymphoma tissue (MALT). Bull Cancer 1991: 78: 2035.
  • 8
    Isaacson PG & Wright DH. Extranodal malignant lymphoma arising from mucosa associated lymphoid tissue. Cancer 1984; 53: 251524.
  • 9
    Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 30711.
  • 10
    Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985; 78(Suppl. 1A): 2932.
  • 11
    Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case–control study. Br Med J 1998; 317: 1801.
  • 12
    Isaacson PG & Wright DH. Intestinal lymphoma associated with malabsorption. Lancet 1978; i: 6770.
  • 13
    Kelly MD, Stuart M, Tschuchnigg M, Turner J, Tydd T. primary intestinal Hodgkin’s disease complicating ileal Crohn’s disease. Aust NZ J Surg 1997; 67: 4859.
  • 14
    Cooper BT, Holmes GK, Ferguson R, Cooke WT. Celiac disease and malignancy. Medicine 1980; 59: 24961.
  • 15
    Shepherd NA, Hall PA, Williams GT, et al. Primary malignant ymphoma of the large intestine complicating chronic inflammatory bowel disease. Histopathology 1989; 15: 32537.
  • 16
    Perosio PM, Brooks JJ, Saul SH, Haller DG. Primary intestinal lymphoma in Crohn’s disease: minute tumour with fatal outcome. Am J Gastroenterol 1991; 87: 8948.
  • 17
    Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology 1999; 117: 14337.
  • 18
    Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer 1992; 69: 111923.
  • 19
    Friedman HB, Silver GM, Brown CH. Lymphoma of the colon simulating ulcerative colitis: report of four cases. Am J Dig Dis 1968; 13: 9107.
  • 20
    Robert ME, Kuo FC, Longtine JA, et al. Diffuse colonic mantle cell lymphoma in a patient with presumed ulcerative colitis. Am J Surg Path 1996; 20: 102431.
  • 21
    Son HJ, Rhee PL, Kim JJ, et al. Primary T cell lymphoma of the colon. Korean J Intern Med 1997; 12: 23841.
  • 22
    Camera L, Della Noce M, Cirillo LC. Primary ileo-cecal lymphoma mimicking Crohn’s disease. Report of a case (Italian). Radiologia Med 1997; 94: 1224.
  • 23
    Shepherd NA. Pathological mimics of chronic inflammatory bowel disease. J Clin Pathol 1991; 44: 72633.
  • 24
    Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JAH, Allan RN. Malignancy in Crohn’s disease. Gut 1980; 21: 10249.
  • 25
    Prior P, Gyde SN, Macartney JC, Thompson H, Waterhouse JAH, Allan RN. Cancer morbidity in ulcerative colitis. Gut 1982; 23: 4907.
  • 26
    Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985; 56: 291421.
  • 27
    Ekbom A, Helmick C, Zack M, Adami H-O. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 20159.
  • 28
    Bernstein CN, Kliewer E, Rawsthorne P, Doig W, Blanchard JF. Diagnosis of extra-intestinal manifestations and cancers in IBD in large population-based databases. Gastroenterology 1998; 114: A930A930(Abstract).
  • 29
    O'Dell KE, Stukenborg GJ, Connors AF, Cominelli F. A potential increased risk of lymphatic and/or hematologic neoplasms among Crohn’s disease and rheumatoid arthritis patients admitted to the University of Virginia Health Centre: a four year retrospective study. Gastroenterology 1998; 114: A1053A1053(Abstract).
  • 30
    Arseneau KO, Stukenborg GJ, Connors AF, Cominelli F. The incidence of non-Hodgkin’s lymphoma in hospitalised Crohn’s disease patients in Virginia—an administrative database study. Gastroenterology 1999; 116: A664A664(Abstract).
  • 31
    Loftus EV, Tremaine WJ, Haberermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ . Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000; 95: 230812.
    Direct Link:
  • 32
    Masel SL & Hanauer SB. Increased association of lymphoma and inflammatory bowel disease. Gastroenterology 2000; 118(Suppl. 2): A119A119(Abstract).
  • 33
    Farrell RJ, Ang Y, Kileen P, et al. Increased risk of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunomosuppressive therapy but overall risk is low. Gut; 2000; 47: 5149(Abstract).
  • 34
    Palli D, Trallori G, Bagnoli S, et al. Hodgkin’s disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000; 119: 64753.
  • 35
    Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Are patients with inflammatory bowel disease (IBD) at increased risk for lymphoma? Gastroenterology 2000; 118(Suppl. 2): A869A869(Abstract).
  • 36
    Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118: S6882.
  • 37
    Larvol L & Soule JC. Reversible lymphoma in the setting of azathioprine therapy for Crohn’s disease. N Engl J Med 1994; 331: 8834.
  • 38
    Hoover R & Fraumeni JF. Risk of cancer in renal-transplant recipients. Lancet 1973; ii: 557.
  • 39
    Kinlen LJ, Sheil AGR, Peto J, Doll R. Collaborative United Kingdom–Australian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979; ii: 14616.
  • 40
    Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive therapy. Am J Med 1985; 78: 449.
  • 41
    Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989; 111: 6419.
  • 42
    Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncolgy 2000; 11(Suppl. 1): 458.
  • 43
    Das KM, Valenzuela I, Morecki R. Crohn’s disease lymph node homogenates produce murine lymphoma in athymic mice. Proc Natl Acad Sci USA 1980; 77: 58892.
  • 44
    Bouhnik Y, Lemann M, Mary J-Y, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 2159.
  • 45
    Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 124952.
  • 46
    Fraser AG, Orchard TR, Jewell DP. Long-term risk of malignancy after treatment of IBD with azathioprine: a 30 year study. Gut 2000; 46(Suppl. II:): A12A12(Abstract).
  • 47
    Lewis JD, Schwartz JS, Lightenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroeneterology 2000; 118: 101824.
  • 48
    Lemann M, Valussiere GD, Bouhnik Y, et al. Intravenous cyclosporine for refractory attacks of Crohn’s disease (CD): Long-term follow-up of patients. Gastroenterology 1998; 114: A1020A1020(Abstract).
  • 49
    Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralises TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995; 7: 2519.DOI: 10.1006/cyto.1995.0029
  • 50
    Bazzoni F & Beutler B. The tumour necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 171725.
  • 51
    Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumour necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994; 94: 74960.
  • 52
    Hanauer S, Schaible T, DeWoody K, et al. Long-term follow-up of patients treated with infliximab (anti-TNF antibody) in clinical trials. Gastroenterology 2000; 118(Suppl. 2): A566A566(Abstract).
  • 53
    Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13(Suppl. 4): 1622.
  • 54
    Lofberg R, Rutgeerts P, Van Deventer SJH, et al. Long-term safety follow-up of patients treated with infliximab (anti TNFα antibody, remicade) in clinical trials. Gut 2000 47(Suppl. 3): A245A245(Abstract).